Trexquant Investment LP purchased a new stake in shares of LHC Group, Inc. (NASDAQ:LHCG) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 24,853 shares of the health services provider’s stock, valued at approximately $2,755,000.

A number of other large investors have also bought and sold shares of LHCG. Parallel Advisors LLC raised its position in LHC Group by 790.0% during the first quarter. Parallel Advisors LLC now owns 267 shares of the health services provider’s stock valued at $30,000 after buying an additional 237 shares during the period. Sageworth Trust Co purchased a new position in LHC Group in the first quarter valued at about $36,000. Financial Gravity Companies Inc. purchased a new position in LHC Group in the fourth quarter valued at about $49,000. Quadrant Capital Group LLC grew its stake in LHC Group by 1,045.7% in the first quarter. Quadrant Capital Group LLC now owns 527 shares of the health services provider’s stock valued at $57,000 after purchasing an additional 481 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in LHC Group in the first quarter valued at about $68,000. 91.42% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have commented on LHCG shares. UBS Group set a $133.00 target price on LHC Group and gave the company a “buy” rating in a research note on Friday, May 10th. Jefferies Financial Group boosted their target price on LHC Group from $125.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. BidaskClub upgraded LHC Group from a “hold” rating to a “buy” rating in a research note on Tuesday, April 30th. SunTrust Banks boosted their target price on LHC Group to $130.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Zacks Investment Research upgraded LHC Group from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a research note on Thursday, June 6th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $120.58.

In other news, COO Donald Dwayne Stelly sold 448 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $120.00, for a total transaction of $53,760.00. Following the completion of the sale, the chief operating officer now owns 91,252 shares in the company, valued at approximately $10,950,240. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ronald T. Nixon sold 12,000 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $117.20, for a total value of $1,406,400.00. Following the sale, the director now owns 29,100 shares of the company’s stock, valued at approximately $3,410,520. The disclosure for this sale can be found here. In the last quarter, insiders have sold 59,685 shares of company stock valued at $6,750,989. 5.20% of the stock is currently owned by corporate insiders.

Shares of LHCG traded up $0.28 during trading hours on Wednesday, hitting $115.41. 3,156 shares of the company were exchanged, compared to its average volume of 250,695. The company has a market cap of $3.62 billion, a PE ratio of 32.53, a price-to-earnings-growth ratio of 1.96 and a beta of 0.83. LHC Group, Inc. has a 52 week low of $79.09 and a 52 week high of $122.20. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.57 and a current ratio of 1.57.

LHC Group (NASDAQ:LHCG) last released its quarterly earnings results on Wednesday, May 8th. The health services provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.08. The company had revenue of $502.59 million during the quarter, compared to the consensus estimate of $511.16 million. LHC Group had a return on equity of 8.43% and a net margin of 3.83%. On average, research analysts predict that LHC Group, Inc. will post 4.3 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/24853-shares-in-lhc-group-inc-nasdaqlhcg-acquired-by-trexquant-investment-lp/3039429.html.

LHC Group Profile

LHC Group, Inc provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Home & Community-Based Services, Facility-Based Services and Healthcare Innovations.

Further Reading: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding LHCG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LHC Group, Inc. (NASDAQ:LHCG).

Institutional Ownership by Quarter for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.